Corey Lager, MD
Endocrinology, Diabetes & Metabolism · Portage, MINPI 1295171189
Payments from drug & device makers
Across 134 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$970
- Chiesi USA, Inc.$625
- Regeneron Healthcare Solutions, Inc.$201
- Amgen$194
- Novo Nordisk$187
- Novartis$180
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$62516%
- Travel & lodging$76720%
- Food & beverage$2,44563%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 7 | $970 |
| Chiesi USA, Inc. | 2 | $625 |
| Regeneron Healthcare Solutions, Inc. | 1 | $201 |
| Amgen(2 entities) | 11 | $194 |
| Novo Nordisk | 12 | $187 |
| Novartis | 16 | $180 |
| Lilly USA, LLC | 12 | $178 |
| Abbott | 9 | $170 |
| Insulet Corporation | 10 | $147 |
| Valeritas, Inc. | 2 | $92 |
| Dexcom, Inc. | 5 | $90 |
| Mannkind Corporation | 3 | $84 |
| Corcept Therapeutics | 5 | $81 |
| Xeris Pharmaceuticals, Inc. | 5 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $75 |
| Neurocrine Biosciences, Inc. | 2 | $64 |
| Medtronic(2 entities) | 3 | $62 |
| Bayer | 3 | $43 |
| Sequel Med Tech, LLC | 2 | $35 |
| Pfizer | 2 | $34 |
| Companion Medical, Inc. | 2 | $34 |
| Shire North American Group Inc | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $23 |
| Merck | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Cequr Corporation | 1 | $13 |
| AstraZeneca | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$901
- MYCAPSSA$625
- LIBTAYO$201
How this compares
$3,892 in reported general payments places this provider in the 60th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 183 | $233,370 |
| OzempicSemaglutide | 119 | $210,871 |
| JardianceEmpagliflozin | 111 | $131,664 |
| TrulicityDulaglutide | 83 | $111,583 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $96,858 |
| FarxigaDapagliflozin Propanediol | 54 | $76,891 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $50,014 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 17 | $44,950 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $43,151 |
| Humulin R U-500Insulin Regular, Human | 16 | $36,719 |
| JanuviaSitagliptin Phosphate | 27 | $36,188 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $35,929 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $29,867 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 27 | $28,308 |
| HumalogInsulin Lispro | 54 | $23,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi | $178 | $374,484332 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $187 | $277,858194 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi | $23 | $170,255151 claims |
| AstraZenecaFarxiga | $12 | $76,89154 claims |
| MerckJanuvia | $23 | $36,18827 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $75 | $22,60711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $28 | $11,672774 claims |
| AbbVieSynthroid | $16 | $9,07296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Portage
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.